Promoter methylation analysis using the UALCAN database revealed that THBS2, CTNNB1, COL4A1, and E2F3 exhibited significantly lower promoter methylation levels in STAD tumor tissues compared to normal controls (Fig. 4 A). This evidence concerns the gene E2F3 and neoplasm.